Amgen (NASDAQ: AMGN) — Company Overview, News & Financial Data
Amgen is a biotechnology company focused on developing innovative therapeutics across oncology, cardiovascular disease, and more.
Amgen
Amgen is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses. Headquartered in Thousand Oaks, California, the company concentrates on key therapeutic areas including oncology, inflammation, general medicine, bone health, cardiovascular diseases, and rare diseases, alongside a growing portfolio of biosimilars. Amgen utilizes advanced human genetics and recombinant DNA technology to isolate, develop, and manufacture biological medicines for patients worldwide. Its operational capabilities encompass integrated research laboratories, clinical trial infrastructure, process development, and commercial-scale manufacturing facilities operating across North America, Europe, Asia-Pacific, and other international regions.
Snapshot
Operations
Products and/or services of Amgen
- Oncology Therapies: Discovery, production, and distribution of targeted biologic cancer therapies and immunotherapies that treat solid tumors and hematologic malignancies, including treatments for lung cancer, multiple myeloma, acute lymphoblastic leukemia, and prostate cancer in international healthcare markets.
- Inflammation Therapies: Development and commercialization of biologic and oral medicines for autoimmune and chronic inflammatory conditions, focusing on systemic treatments for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, severe asthma, and moderate-to-severe inflammatory skin disorders across global patient populations.
- General Medicine and Bone Health: Manufacturing and global delivery of biopharmaceutical products designed for cardiovascular conditions and bone health, providing therapeutics to lower LDL cholesterol, reduce cardiovascular event risks, and treat postmenopausal osteoporosis and bone metastases.
- Rare Disease Treatments: Provision of specialized targeted biopharmaceuticals designed to treat complex rare diseases, including targeted clinical therapies for thyroid eye disease, chronic refractory gout, neuromyelitis optica spectrum disorder, and rare systemic inflammatory conditions worldwide.
- Biosimilars Portfolio: Development, scale-up manufacturing, and commercial distribution of high-quality biosimilar medicines designed to provide broader patient access to alternative biologic therapies across oncology, immunology, and supportive care segments in major international markets.
- Biomanufacturing and R&D: Operation of advanced biotechnology research and development laboratories alongside large-scale commercial biopharmaceutical production facilities, utilizing cell culture technology, single-use bioreactors, and automated fill-finish processes to maintain global medicine supply chains.
Amgen executive team
- Robert A. BradwayChairman & CEO
- Murdo GordonExecutive Vice President of Global Markets and Policy
- Peter H. GriffithExecutive Vice President
- James E. BradnerEVP of Research & Development, Artificial Intelligence and Data
- Thomas J. W. DittrichExecutive VP & CFO
- Esteban SantosExecutive Vice President of Operations
- Matthew C. BuschChief Accounting Officer & VP of Finance
- Sean BruichSVP & Chief Technology Officer
- Scott SkellengerSenior VP & Chief Information Officer
- Howard Y. ChangSenior VP of Global Research & Chief Scientific Officer
Latest news about Amgen
Amgen reports Sjogren’s drug trial success
United StatesAmgen reduces IMDELLTRA monitoring to 6-8 hours
United StatesAmgen reports Repatha 20% death risk reduction
United StatesTEZSPIRE trial shows EoE improvements at week 52
United StatesAmgen TEZSPIRE trial shows EoE improvements
United StatesWhy dominant pharmaceutical firms are paying billion-dollar premiums for immunology assets
United States
Dividend history
Dividends per share paid by Amgen, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $10.0800 |
| FY2025 | — | — | — | $9.5200 |
| FY2024 | — | — | — | $9.0000 |
| FY2023 | — | — | — | $8.5200 |
| FY2022 | — | — | — | $7.7600 |
Key financials
Reported results for Amgen, in USD.
- Market cap
- 249.1B
- Revenue (TTM)
- 38.1B
- P/E ratio
- 28.6
- EPS (diluted, TTM)
- 16.1
- Dividend yield
- 2.2%
- Profit margin
- 22.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 36.7B | 10.7B | 7.7B | |
| 33.4B | 7.3B | 4.1B | |
| 28.2B | 7.9B | 6.7B | |
| 26.3B | 9.6B | 6.6B |